Contact: [email protected]
| Title | Characteristics | Line | Study information |
|---|---|---|---|
| CAMBRIA-1 | HER2- / HR+ | Adjuvant | Camizestrant vs. SOC ET; 2-5y on adj ET |
| TROPION-Breast03 | TNBC (no BRCA1/2) | Adjuvant | Dato-DXd + Durva vs. Dato-DXd vs. SOC; resid. inv. disease and/or axillary lymph nodes present after surgery |
| TACTIVE-U/C4891024 | HER2- / ER+ | 1-3L | ARV-471 oral Proteolysis Targeting Chimera; prior CDK4/6 required |
| Opera-01 | HER2- / ER+ | 2-3L | OP-1250 Palazestrant vs. SOC; prior CDK4/6 required; no prior chemo |
| ELECTRA/ELA-0121 | HER2- / ER+ | 2-3L | Elacestrant + Abemaciclib |
| C4891001/Veritac-2 | HER2- / ER+ | 2-3L | ARV-471 oral Proteolysis Targeting Chimera vs. Fulvestrant; no prior chemo |
| VIKTORIA-1/CELC-G-301 | HER2- / ER+ | 2-3L | Gedatolisib PI3K inhibitor + Palbociclib + Fulvestrant vs. Gedatolisib + Fulvestrant; no prior chemo |
| INAVO121/WO43919 | HER2- / ER+ | 2-3L | PIK3CA mutated; Inavolisib + Fulvestrant vs. Alpelisib + Fulvestrant |
| AIPAC-003 | TNBC and HER2-/HR+ | 1L chemo | Paclitaxel + eftilagimod alpha; no prior chemo |